Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists-Reference-Cited by-同舟云学术

Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists

Published:2015-04-21 Issue:7 Volume:75 Page:809-816
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

McKeage Kate

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-015-0393-y.pdf

Reference29 articles.

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2014 (updated). http://www.ginasthma.org/ . Accessed 23 Mar 2015.

2. Chung KF, Wenzel S, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Resp J. 2014;43:343–73.

3. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat® Soft Mist™ inhaler. Int J Pharm. 2004;283:1–9.

4. Keating GM. Tiotropium Respimat® Soft Mist™ inhaler: a review of Its use in chronic obstructive pulmonary disease. Drugs. 2014;74(15):1801–16.

5. Keating GM. Tiotropium bromide inhalation powder. Drugs. 2012;72(2):273–300.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of tiotropium in combination with olodaterol on house dust mite-induced allergic airway disease;Pulmonary Pharmacology & Therapeutics;2017-08

2. Activation of the mTOR signaling pathway is required for asthma onset;Scientific Reports;2017-07-03

3. Long-term safety of tiotropium delivered by Respimat^® SoftMist™ Inhaler: patient selection and special considerations;Therapeutics and Clinical Risk Management;2016-09

4. Traditional Therapies for Severe Asthma;Immunology and Allergy Clinics of North America;2016-08

5. Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema;Expert Review of Clinical Pharmacology;2016-04-07